Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 6, 2013, Pages 1473-1483

  Deeken, J F ^a   Shimkus, B ^b   Liem, A ^c   Hill, D ^d   Gurtler, J ^e   Berghorn, E ^f   Townes, L ^f   Lu, H ^f   Trifan, O ^f   Zhang, S ^f  

^a GEORGETOWN UNIVERSITY   (United States)

^b South Austin Cancer Center   (United States)

^c Pacific Shores Medical Group   (United States)

^d Tri Valley Cancer Research and Treatment Center   (United States)

^e Metairie Oncologists   (United States)

^f BRISTOL MYERS SQUIBB   (United States)

Author keywords

Arrhythmias; Cancer; Cetuximab; QTc interval; Targeted therapy

Indexed keywords

CETUXIMAB;

ABDOMINAL PAIN; ACNE; ACUTE CORONARY SYNDROME; ADULT; AGED; ANEMIA; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BLISTER; BRONCHOSPASM; CANCER PATIENT; CHILL; CHOLESTASIS; COLORECTAL CANCER; CONCENTRATION RESPONSE; DERMATITIS ACNEIFORM; DIARRHEA; DIGESTIVE SYSTEM INJURY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; ELECTROCARDIOGRAPHY MONITORING; ELECTROCORTICOGRAPHY; FATIGUE; FEMALE; HEAD AND NECK CANCER; HEART INFARCTION; HEART RATE; HUMAN; HYDRONEPHROSIS; HYPOKALEMIA; INTESTINE OBSTRUCTION; JOINT DISLOCATION; LUNG CANCER; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NECK PAIN; PANCREAS CARCINOMA; PLEURA EFFUSION; PR INTERVAL; PRIORITY JOURNAL; PRURITUS; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; SEPSIS; SIDE EFFECT; SKIN DISEASE; SOLID TUMOR; THORAX PAIN; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HEART; HUMANS; INFUSIONS, INTRAVENOUS; LONG QT SYNDROME; MALE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME; UNITED STATES;

EID: 84878627638     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2146-5     Document Type: Article

References (34)

1. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM (2010) Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. JNCI 102:14-25
2. Ederhy S, Izzedine H, Massard C, Dufaitre G, Spano JP, Milano G et al (2011) Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol/Hematol 80:369-379
3. Brana I, Taberno J (2010) Cardiotoxicity. Ann Oncol 21(Suppl 7):vii173-vii179
4. Yeh ETH, Bickford CL (2009) Cardiovascular complications of cancer therapy. J Am Coll Cardiol 53:2231-2247
5. Mirvis DM, Goldberger AL (2005) Electrocardiography. In: Zipes DP, Libby P, Braunwald E, Bonow RO (eds) Braunwald's heart disease: a textbook of cardiovascular medicine, 7th edn. Saunders, Philadelphia, pp 107-151
6. Belardinelli L, Antzelevitch C, Vos MA (2003) Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 24:619-625
7. Bazett HC (1920) An analysis of the time relationship of electrocardiograms. Heart 7:353-370
8. Fridericia LS (1920) Die Systolendauer im Elektrokardiogramm bei normalen menschen und bei herzkranken [letter]. Acta Med Scand 53:489
9. Hodges M, Salerno Q, Erlien D (1983) Bazett's QT correction reviewed. Evidence that a linear QT correction for heart rate is better (abstract). J Am Coll Cardiol 1:694
10. Sagie A, Larson MG, Goldberg RJ, Bengtson JR, Levy D (1992) An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol 70:797-801
11. Strevel EL, Ing DJ, Siu LL (2007) Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 25:3362-3371
12. Bagnes C, Panchuk PN, Recondo G (2010) Antineoplastic chemotherapy induced QTc prolongation. Curr Drug Safety 5:93-96
13. Raschi E, Vasina V, Ursino MG, Boriani G, Martoni A, De Ponti F (2010) Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy. Pharmacol Ther 125:196-218
14. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH (2002) Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:2215-2220
15. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Steering Committee: ICH Harmonized Tripartite Guideline: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs, E14. Geneva, Switzerland, ICH 2005. Available at: http://www.ich.org/products/ guidelines/efficacy/article/efficacy-guidelines.html
16. FDA Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs 2006. Available at: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ UCM129357.pdf
17. National Cancer Institute: Cancer therapy evaluation program, Common terminology for adverse events, version 3.0 DCTD, NCI, NIH, DHHS, 2006. Available from: http://ctep.cancer.gov/forms/CTCAEv3.pdf
18. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1:1311-1318
19. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345
20. Jonker DJ, O'Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048
21. Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765
22. Van Cutsem E, Kohne C-H, Lang I et al (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011-2019
23. Bonner JA, Harai PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 345:567-578
24. Burtness G, Goldwasser MA, Flood W, Mattar B, Forastiere AA (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer. An Eastern Cooperative Oncology Group study. J Clin Oncol 23:8646-8654
25. Vermorkin JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127
26. Guidance for industry, E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs, 2005. Available at http://www.fda.gov/cder/Guidance/6922fnl.pdf
27. Garnett CE, Beasley N, Bhattaram VA et al (2007) Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol 48:13-18
28. Fracasso PM, Howard Burris III, Arquette MA et al (2007) Pharmacodynamic rationale for dosing study of cetuximab: pharmacokinetic and a phase 1 escalating single-dose and weekly fixed-dose. Clin Cancer Res 13:986-993
29. Pettrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S (2012) Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opin Drug Saf 11(Suppl 1):S9-S19
30. Raschi E, De Ponti F (2012) Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology. Intern Emerg Med 7:113-131
31. Albini A, Cesana E, Dontaelli F, Cammarota R, Bucci EO, Baravelli M et al (2011) Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors. Futur Cardiol 7:693-704
32. Keating GM (2010) Panitumumab: a review of its use in metastatic colorectal cancer. Drugs 70:1059-1078
33. NCT01412957: A Phase 3, Multicenter, Randomized, Open-label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects with Chemorefractory Wild-type KRAS Metastatic Colorectal Cancer. Available at: http://www.clinicaltrials.gov/ct2/ show/NCT01412957?id=NCT01412957&rank=1. Accessed 12 July 2012
34. Al-Khatib SM, Allen La Pointe NM, Kramer JM, Califf RM (2003) What clinicians should know about the QT interval. JAMA 30:2120-2127